title: Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.
abstract: OBJECTIVE
  A significant proportion of patients with rheumatoid arthritis do not respond adequately to biologic treatment. We hypothesized that lack of response to (biologic) disease-modifying antirheumatic drugs (DMARDs) is high in patients in whom the subjective, patient-reported component of the Disease Activity Score 28 (DAS28) is high at baseline. The primary aim of our present study was to investigate the contribution of the more subjective versus the objective components of the DAS28 to response to biologic agents in RA patients, as well as the changes in this contribution over time. The secondary aim was to examine whether the value of this subjective contribution at baseline affects the response to treatment.
  
  
  METHODS
  The DAS28-P (the subjective components of the DAS28 relative to the total DAS28) was calculated. Patients were derived from the computer-assisted Management in Early Rheumatoid Arthritis Trial-II and the Biologicals and Outcome Compared and Predicted in Utrecht Region in Rheumatoid Arthritis Study. Ordinal logistic regression analyses were performed.
  
  
  RESULTS
  The DAS28-P score at baseline was not associated with the level of response according to European League Against Rheumatism criteria at 3 months. Overall, a significant reduction in the DAS28-P score was observed 3 months after start of treatment, showing a greater reduction of the combined subjective components in good responders.
  
  
  CONCLUSIONS
  The results reject the hypothesis that the lack of response to biologic DMARDs is especially high in patients in whom the patient-reported component of the DAS28 is high at baseline; these subjective components are not linked to treatment response.
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Maud S
authors.initials: MS
authors.lastname: Jurgens
authors.affiliation: Utrecht University, Utrecht, The Netherlands.
authors.forename: Cécile L
authors.initials: CL
authors.lastname: Overman
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Johannes W G
authors.initials: JW
authors.lastname: Jacobs
authors.affiliation: University Medical Center Utrecht and Utrecht University, Utrecht, The, Netherlands.
authors.forename: Rinie
authors.initials: R
authors.lastname: Geenen
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Bart V J
authors.initials: BV
authors.lastname: Cuppen
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Anne C A
authors.initials: AC
authors.lastname: Marijnissen
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Johannes W J
authors.initials: JW
authors.lastname: Bijlsma
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Paco M J
authors.initials: PM
authors.lastname: Welsing
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Floris P J G
authors.initials: FP
authors.lastname: Lafeber
authors.affiliation: University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: van Laar
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy; D001688:Biological Products / Q000627:therapeutic use; D004311:Double-Blind Method; D057566:Self Report / Q000592:standards; D012720:Severity of Illness Index; D016896:Treatment Outcome; D064887:Observational Studies as Topic; D016032:Randomized Controlled Trials as Topic; D015337:Multicenter Studies as Topic
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products